Adherex Technologies Expands PEDMARK's Reach into Larger AYA Market Following Record Q1 Revenue
Fennec Pharmaceuticals reported record first-quarter revenue of $15.1 million for its product PEDMARK, which prevents cisplatin-related hearing loss. The company is expanding sales efforts to target over 5,400 U.S. treatment sites and focusing on the larger adolescent and young adult (AYA) market.
Topics: commercial expansion pharmaceuticals product performance